FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 375 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Growing the Cancer Research Pipeline by Expanding Opportunities August 29, 2024 ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ February 3, 2021 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 Load more HOT NEWS Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer Body Location May Influence Fate of Cells with Cancer-Causing Mutations “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients...
